Skip to main content
ZIM Laboratories Limited logo

ZIM Laboratories Limited — Investor Relations & Filings

Ticker · ZIMLAB ISIN · INE518E01015 LEI · 335800YPYG1O3ML66R52 BSE.NS Manufacturing
Open in API
Filings indexed 423 across all filing types
Latest filing 2024-05-14 Report Publication Anno…
Country IN India
Listing BSE.NS ZIMLAB

About ZIM Laboratories Limited

https://www.zimlab.in/

ZIM Laboratories Limited is a research-driven organization specializing in the development and manufacturing of innovative drug delivery solutions. The company focuses on enhancing the efficacy and patient compliance of generic medicines through advanced formulation technologies. Its core product portfolio includes Oral Disintegrating Films (ODF), Oral Disintegrating Tablets (ODT), pellets, and taste-masked granules. Utilizing proprietary technology platforms like Thinoral, the company provides differentiated products across various therapeutic segments, including central nervous system, cardiovascular, and gastrointestinal health. ZIM Laboratories offers end-to-end services from product development and clinical trials to commercial manufacturing. The organization serves a global clientele, providing value-added generic formulations that address specific patient needs such as ease of administration and rapid onset of action.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the publication of financial results for the quarter and year ended 31.03.2024. It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and encloses copies of newspaper publications of the financial results. The document itself is a notification or intimation about the publication of financial results in newspapers, not the financial results report itself. The length is about 15,000 characters, but the content is primarily an announcement of the publication of the financial results, not the detailed financial report or analysis. Therefore, according to the 'Menu vs Meal' rule, this document should be classified as a Report Publication Announcement (RPA) rather than an Interim/Quarterly Report (IR) or Annual Report (10-K).
2024-05-14 English
Updates
Investor Presentation Classification · 95% confidence The document is titled 'Q4 & FY24 Earnings Presentation' and is addressed to stock exchanges pursuant to SEBI regulations, indicating it is an official earnings presentation. It contains detailed financial highlights for Q4 and FY24, including revenue, EBITDA, PAT, business updates, marketing and registrations, and strategic priorities. The document is about 15,000 characters long, which is substantial and contains detailed financial and operational data. The content is consistent with an investor presentation focusing on financials, strategy, and market position rather than a brief earnings release or a full annual report. Therefore, the document fits the category of an Investor Presentation (IP).
2024-05-13 English
Acquisition
Regulatory Filings
2024-05-13 English
Financial Result Updates
Regulatory Filings
2024-05-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a notification about an upcoming earnings conference call for Q4 & FY24, scheduled on May 15, 2024. It includes details such as the date, time, participants, and dial-in information. There are no actual financial results or detailed financial data presented in the document. It is an announcement of the earnings call event rather than the earnings release itself or a transcript of the call. Therefore, the document fits the category of a Call Transcript (CT) announcement or invitation, but since it is only an announcement of the call and not the transcript, the best fitting category is Call Transcript (CT) as it relates directly to the earnings call event.
2024-05-08 English
Board Meeting — ZIM LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 13-May-2024 to inter-alia consider and approve the Audited Financial results of the Company for th…
Regulatory Filings
2024-05-06 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.